Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
Patients with known human immunodeficiency virus (HIV) infection, infectious hepatitis, type A, B or C, active hepatitis, or hepatic insufficiency
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy
Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis A, B, or C (screening is not required).
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C; participants with a history of resolved hepatitis A may be included in the trial
Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus (HIV) infection.
History of human immunodeficiency virus (HIV), interstitial lung disease, active Hepatitis B or Hepatitis C, or ?Grade  immune-related AE with prior immunotherapy
Known immunodeficiency or known to have evidence of acute or chronic or human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C or other uncontrolled inter-current illnesses.
Patients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatment
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Known immunodeficiency, human immunodeficiency virus (HIV) positivity, hepatitis B, or hepatitis C
Known human immunodeficiency virus (HIV) infection or active hepatitis B (defined as hepatitis B surface antigenpositive) or C (defined as hepatitis C antibodypositive)
Negative antiviral serology for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
Patients with known active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; patients with a history of hepatitis B or hepatitis C, who are deemed cured and no longer require treatment may be allowed to enroll after consultation with the respective specialist and the study PI
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Subject has known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection or is known to be a carrier of hepatitis B or C.
Known positive test for human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis A, hepatitis B, hepatitis C, or cytomegalovirus (CMV)
Active infection requiring systemic therapy including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) is NOT permitted
Known history of human immunodeficiency virus (HIV) positivity or active hepatitis C or B - chronic asymptomatic viral hepatitis is allowed
Human immunodeficiency virus (HIV), active hepatitis B or C
Patients infected with hepatitis B, C or human immunodeficiency virus (HIV), unless they are on stable and effective antiviral treatment
Patients with conditions requiring immunosuppressive medications or chronic infections (including human immunodeficiency virus [HIV] infection, hepatitis B and C)
Patients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligible
Patients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligible
Active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or tuberculosis infection; patients with a history of cleared hepatitis C (undetectable viral loads) are allowed
Human immunodeficiency virus (HIV), hepatitis B or C documented infections
Patients with known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C are not eligible; Note: Patients do not need to have HIV, hepatitis B, or hepatitis C testing at screening
Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Patients with known chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Serious infections including a history of active hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Subjects who active hepatitis B or C, or human immunodeficiency virus (HIV)
Active hepatitis, known human immunodeficiency virus (HIV), or other condition that requires immunosuppressive therapy, including current use of high dose systemic corticosteroids
No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Known history of active tuberculosis (TB), human immunodeficiency virus (HIV) /, hepatitis B or hepatitis C
Known active infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C or cytomegalovirus (CMV)
Has a known history of human immunodeficiency virus (HIV) (HIV / antibodies), active hepatitis B or hepatitis C
Patients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis
Subjects must not have active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known immunosuppressive disease, autoimmune disease or human immunodeficiency virus infection, hepatitis B or hepatitis C
Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
Patients with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Subject has a known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
An existing diagnosis of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any current laboratory findings or clinical signs and symptoms that suggest these conditions
Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C that has not been documented to be cured
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Human immunodeficiency virus (HIV), hepatitis B, hepatitis C
History of chronic or recurrent infection including but not limited to human immunodeficiency virus (HIV), hepatitis B or hepatitis C
In suspected patients no active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
Patients with known active human immunodeficiency virus (HIV), hepatitis A, hepatitis B, or hepatitis C infection
Patients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection are ineligible
Active infection including human immunodeficiency virus (HIV) and untreated hepatitis B, and hepatitis C. Screening for chronic conditions is not required.
Any evidence of active infection including active Hepatitis B, Hepatitis C or human immunodeficiency virus
Patients with known human immunodeficiency virus, active hepatitis B or active hepatitis C
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Known infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Negative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virus
Participants who have a known active infection requiring systemic therapy, including human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
Known active infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Known chronic infection with human immunodeficiency virus, hepatitis B, or hepatitis C.
Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV) or hepatitis B or C
Evidence of active hepatitis B (HepB), hepatitis C (HepC), or Human Immunodeficiency Virus (HIV) infection.
Evidence for infection including wound infections, Human Immunodeficiency Virus (HIV) or any type of Hepatitis
Subject known to have acute or chronic active hepatitis B, hepatitis C, or human immunodeficiency virus infection will also be excluded.
Patients with human immunodeficiency virus (HIV), chronic hepatitis B, or chronic hepatitis C (known from the existing medical record)
EXCLUSION FOR COLLECTION OF T CELLS/PBMCS: Patients with active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV), active hepatitis B or C, or tuberculosis
Subject has a known history of infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with fever or any active systemic infections, including known human immunodeficiency virus (HIV), hepatitis B or C
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus
Known immunodeficiency or human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; antibody to hepatitis B or C without evidence of active infection may be allowed
Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Hepatitis B or C or human immunodeficiency virus (HIV)
Active infection including tuberculosis, hepatitis B or C, or human immunodeficiency virus.
Human immunodeficiency virus (HIV)-positive patients or with history of hepatitis or with current chronic or active hepatitis; a past history of hepatitis A is allowed
History of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.
Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV);
Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapy
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with known human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active or carriers)
COHORT A: No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (negative screening tests required)
Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV), active hepatitis B or hepatitis C infection
Known infection with human immunodeficiency virus, Hepatitis B, or Hepatitis C
Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis
Active human immunodeficiency virus (HIV), hepatitis B and hepatitis C
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus or hepatitis C, or active infection with hepatitis B or C
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, or hepatitis C infection
Comorbid conditions: Addisons disease, autoimmune hepatitis, hepatitis B, hepatitis C, acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV), lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; patients should be assessed for high risk behaviors that may result in these infections, such as intravenous drug use or multiple sexual partners; the assessment should be noted
Patients with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C infection are ineligible
Human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C infection
Patients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
Subjects known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening
Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C within the year prior to enrollment (note: for guidance in defining active infection for hepatitis B, please refer to the WHO guidelines)
Uncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
Subject has known historical or active infection with HIV (human immunodeficiency virus), hepatitis B, or hepatitis C or subject receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the Investigator, increase the risk of serious neutropenic complications.
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known clinically significant infections, including human immunodeficiency virus (HIV) and active hepatitis B or C
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (hepatitis B or hepatitis C)
Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, or HIV-seropositive
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Clinically significant infections including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C
Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses
Patients with known active hepatitis B, C or human immunodeficiency virus (HIV) infections on initial assessment
Known human immunodeficiency virus (HIV) infection or active hepatitis B (defined as hepatitis B surface antigenpositive) or C (defined as hepatitis C antibodypositive)
Human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; negative screening tests for HIV, hepatitis B, and hepatitis C are required
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded because of potential effects on immune function and/ or possible drug interactions
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections are excluded
Infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Current evidence or previous medical history of (ie, any absolute risk of latent infection) hepatitis B or C, any active hepatitis, or human immunodeficiency virus (HIV) infection. Active clinically serious infections > CTCAE Grade .
Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known human immunodeficiency virus, Hepatitis B or Hepatitis C infection.
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C due to confounding effects on immune system
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection due to confounding effects on immune function
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection
Active infection including tuberculosis (TB), hepatitis B, hepatitis C, or human immunodeficiency virus. Note: TB testing will be at the discretion of the treating physician and should be in line with local practice
Positive history of human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C or severe/uncontrolled intercurrent illness or infection
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Patients with active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Patients must not have known history of hepatitis B, hepatitis C, human immunodeficiency virus (HIV); the use of physiologic doses of corticosteroids may be approved after consultation with the study chair
History of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C
Past history of tuberculosis (TB) or active infection with TB, human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
Patients with a diagnosis of hepatitis or human immunodeficiency virus (HIV)
History of human immunodeficiency virus (HIV) or active hepatitis C
History of human immunodeficiency virus (HIV), hepatitis B, or active hepatitis C infection
Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses
History of or active hepatitis B or hepatitis C or human immunodeficiency virus (HIV) infection
Subjects must not have a history of human immunodeficiency virus, hepatitis B, or hepatitis C, except for the following:
Participants with known human immunodeficiency virus (HIV) infection, hepatitis B carrier state or with clinical evidence of hepatitis B